Viridian Therapeutics, Inc.\DE — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Viridian Therapeutics, Inc.\DE filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $5.71M | Mar 21, 2016 |
| FY2015 | Dec 31, 2014 | $6.48M | Mar 21, 2016 |
| FY2014 | Dec 31, 2013 | $5.49M | Mar 27, 2015 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $1.19M | Mar 15, 2018 |
| FY2017 | Sep 30, 2017 | $1.63M | Mar 15, 2018 |
| FY2017 | Jun 30, 2017 | $718.0K | Mar 15, 2018 |
| FY2017 | Mar 31, 2017 | $462.0K | Mar 15, 2018 |
| FY2017 | Dec 31, 2016 | $509.0K | Mar 15, 2018 |
| FY2017 | Sep 30, 2016 | $936.0K | Mar 15, 2018 |
| FY2017 | Jun 30, 2016 | $1.12M | Mar 15, 2018 |
| FY2017 | Mar 31, 2016 | $917.0K | Mar 15, 2018 |
| FY2016 | Dec 31, 2015 | $2.54M | Mar 24, 2017 |
| FY2015 | Dec 31, 2014 | $4.32M | Mar 21, 2016 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($342.60M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($269.95M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($237.73M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($129.87M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | ($79.41M) | Feb 27, 2024 |
| FY2021 | Dec 31, 2020 | ($110.72M) | Mar 11, 2022 |
| FY2019 | Dec 31, 2019 | ($10.12M) | Mar 13, 2020 |
| FY2019 | Sep 30, 2019 | ($11.23M) | Mar 13, 2020 |
| FY2019 | Jun 30, 2019 | ($8.90M) | Mar 13, 2020 |
| FY2019 | Mar 31, 2019 | ($11.63M) | Mar 13, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($363.40M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($299.04M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($254.45M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($134.30M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | ($79.73M) | Feb 27, 2024 |
| FY2021 | Dec 31, 2020 | ($110.38M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($41.98M) | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | ($33.08M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($26.53M) | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | ($16.99M) | Mar 15, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $8.42M | Mar 13, 2020 |
| FY2019 | Sep 30, 2019 | $9.03M | Mar 13, 2020 |
| FY2019 | Jun 30, 2019 | $8.60M | Mar 13, 2020 |
| FY2019 | Mar 31, 2019 | $8.75M | Mar 13, 2020 |
| FY2019 | Dec 31, 2018 | $8.23M | Mar 13, 2020 |
| FY2019 | Sep 30, 2018 | $7.40M | Mar 13, 2020 |
| FY2019 | Jun 30, 2018 | $8.38M | Mar 13, 2020 |
| FY2019 | Mar 31, 2018 | $6.41M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $5.00M | Mar 14, 2019 |
| FY2018 | Sep 30, 2017 | $5.02M | Mar 14, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $95.32M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $61.08M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $95.00M | Feb 26, 2026 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($276.39M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($232.32M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($184.17M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($93.84M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | ($54.58M) | Feb 27, 2024 |
| FY2021 | Dec 31, 2020 | ($29.78M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($36.06M) | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | ($26.84M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($28.17M) | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | ($14.76M) | Mar 15, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $495.0K | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $511.0K | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $898.0K | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $797.0K | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $338.0K | Feb 27, 2024 |
| FY2021 | Dec 31, 2020 | $42.0K | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $84.0K | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $445.0K | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $246.0K | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $250.0K | Mar 15, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $899.42M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $742.40M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $490.42M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $435.09M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $203.71M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $131.26M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $30.26M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $66.15M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $52.48M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $24.76M | Mar 15, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $177.25M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $70.76M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $48.40M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $40.03M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $15.99M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $11.22M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $14.51M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $14.80M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $13.97M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $9.71M | Mar 15, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $722.17M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $671.64M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $442.02M | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | $395.06M | Feb 26, 2026 |
| FY2024 | Dec 31, 2021 | $187.72M | Mar 3, 2025 |
| FY2023 | Dec 31, 2020 | $120.04M | Feb 27, 2024 |
| FY2021 | Dec 31, 2019 | $15.75M | Mar 11, 2022 |
| FY2020 | Dec 31, 2018 | $51.34M | Mar 26, 2021 |
| FY2019 | Dec 31, 2017 | $38.51M | Mar 13, 2020 |
| FY2018 | Dec 31, 2016 | ($61.92M) | Mar 14, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.34B) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($995.86M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($725.91M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | ($488.17M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($358.30M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($278.89M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($168.17M) | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | ($126.30M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($93.59M) | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | ($67.08M) | Mar 15, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $32.61M | Mar 14, 2019 |
| FY2018 | Dec 31, 2017 | $47.44M | Mar 14, 2019 |
| FY2018 | Dec 31, 2016 | $22.10M | Mar 14, 2019 |
| FY2017 | Dec 31, 2015 | $21.24M | Mar 15, 2018 |
| FY2016 | Dec 31, 2014 | $5.12M | Mar 24, 2017 |
| FY2015 | Dec 31, 2013 | $209.0K | Mar 21, 2016 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $20.21M | Feb 27, 2024 |
| FY2023 | Dec 31, 2022 | $4.65M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Mar 9, 2023 |
| FY2019 | Dec 31, 2019 | $7.67M | Mar 13, 2020 |
| FY2018 | Dec 31, 2018 | $10.00M | Mar 14, 2019 |
| FY2017 | Dec 31, 2017 | $10.00M | Mar 15, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | (5) | Feb 27, 2024 |
| FY2023 | Dec 31, 2022 | (4) | Feb 27, 2024 |
| FY2023 | Dec 31, 2021 | (6) | Feb 27, 2024 |
| FY2021 | Dec 31, 2020 | (31) | Mar 11, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | (5) | Feb 27, 2024 |
| FY2023 | Dec 31, 2022 | (4) | Feb 27, 2024 |
| FY2023 | Dec 31, 2021 | (6) | Feb 27, 2024 |
| FY2021 | Dec 31, 2020 | (31) | Mar 11, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 101.83M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 80.99M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 53.99M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | 41.31M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | 23.92M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | 4.23M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | 2.32M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | 30.84M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | 22.57M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | 833,744 | Mar 15, 2018 |